Systemic alpha-radiotherapy with radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC). Clinical experience of using the drug in Sverdlovsk Regional Oncological Dispensary, Yekaterinburg

Patients with metastatic castration-resistant prostate cancer (mCRPC) are a complex and heterogeneous group, and the main goal of their treatment includes both increase in life expectancy and maintenance of its quality. The most common localization of metastasis of prostate cancer (PCa) is the bones of the skeleton, which is associated with a high risk of skeletal complications and implies difficulties to further treatment of this group of patients. The increase in the incidence of prostate cancer requires the search for new methods of treatment for this category of patients. Currently, there are several therapeutic options for the treatment of mCRPCa: chemotherapy, androgen receptor signaling inhibitors, systemic alpha-radiotherapy. Radium chloride [Ra223] is the first alpha-emitting radiopharmaceutical (RP) approved for the treatment of CRPC patients with bone metastases and the first RP improving overall patient survival. The study was aimed to the evaluation of the efficacy and safety of Ra223 in patients with mCRPC. This analysis included 54 patients with mCRPCa who received 1 to 6 injections of radium-223 [Ra-223] as part of routine clinical practice. Most patients had more than 6 metastases - 92.6%; 4 patients had less than 6 metastases - 7.4%. Radium-223 [Ra223] has been shown to be effective in patients with mCRPCa. The maximum effect of therapy was observed in patients who received 5 or more injections. At the same time, there was a good tolerability of the drug and a low level of toxicity.

bone metastases, castration-resistant prostate cancer, overall survival, radium-223, safety